Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

22
Market Live: Sensex in the red, rupee sinks 35 paise; BJP leads in Karnataka but away from half-way mark

2018-05-15 moneycontrol
Earnings: Pharma major Lupin has posted a loss of Rs 783.5 crore for the quarter ended March 2018, due to one-time loss of Rs 1,464.3 crore on Gavis Group acquisition.
PWQFY 539150 500325 EMAMIINFRA BHUSANSTL RELIANCE PNCINFRA 532810 539437 500470 IDFCBANK RIGD 500570 SNOWMAN TATAMOTORS 500055 RLNIY INDIGO IBN 532605 JBMA 538635 539448 PFC ICICIBANK 533218 ZANDUREALT TTST INDIANHUME TATASTEEL TATLY 532174 504741 506720 TTM

0
Indian Hume Pipe slips 4% on cancellation of LoA worth Rs 578 crore

2018-05-15 moneycontrol
Shares of Indian Hume Pipe Company declined 4 percent intraday Tuesday as company received cancellation of letter of acceptance from Madhya Pradesh Jal Nigam Maryadit.
INDIANHUME 504741

6
Indian Hume Pipe secures Rs ₹578 cr order

2018-04-23 thehindubusinessline
Indian Hume Pipe Company has secured a work order for ₹578.50 crore from Madhya Pradesh Jal Nigam Maryadit for Kundaliya Multi Village Rural Water Supply Scheme for Rajgarh district.
INDIANHUME HDB 500180 HDFCBANK 504741

24
Market Live: Nifty holds 10,550; FMCG index up 2%, Bharti Group stocks gain

2018-04-18 moneycontrol
12:55 pm Earnings Outlook: "We are looking at Sensex earnings. In Q4, earnings will grow in the range of 13-14 percent, which will be double digit growth after a long time. Partially, this will be due to low base of Q4 last year and the other due to better earnings of global commodity companies, be it energy or metals. That will aid overall growth,” Gaurav Dua, Head of Research, Sharekhan told Moneycontrol.
BAJAJ-AUTO ESL AMKD DABUR FEDA ICLQY SIMMOND DBRQY 500096 MAHSCOOTER 534816 UCLQY FEDS 500850 GODREJCP FEDERALBNK EICHERMOT GLENMARK JAGRAN 532705 FDBAY YYBKY 532822 MRZUY ULTRACEMCO 532424 532500 BAJAJFINSV TATASTEEL FORTIS TATLY MARUTI 500266 504741 BHRYY 500469 AMTEKAUTO 532978 532538 532977 BHRQY GLKQY GDRJY 505200 500470 INFRATEL BHARTIARTL INDHOTEL YESBANK ECQRY 500314 ORIENTHOT 533264 UCLQF 532648 532843 532454 TTST INDIANHUME 532296 IDEA 520077 507998

20
Market Live: Sensex consolidates after 9-day gains; hotels stocks extend rally

2018-04-18 moneycontrol
10:55 am Should gold be a part of your portfolio?: Akash Jain, Vice President - Equity Research, Ajcon Global said gold is better as a short to medium-term investment, as long-term returns on the yellow metal are often as low as 10 percent per annum. We would suggest investors not to make too heavy or long-term investments in gold.
BAJAJ-AUTO ESL DABUR 532538 532978 532977 SIMMOND BHRQY DBRQY GLKQY 505200 500096 500470 MAHSCOOTER UCLQY 500850 BHARTIARTL INDHOTEL EICHERMOT GLENMARK YESBANK ECQRY JAGRAN 500314 ORIENTHOT 532705 533264 UCLQF 532648 YYBKY 532843 ULTRACEMCO 532454 BAJAJFINSV TTST 532296 INDIANHUME TATASTEEL FORTIS TATLY 500266 504741 507998

17
Market Live: Sensex off opening high, midcaps outperform; Mindtree hits new high

2018-04-18 moneycontrol
9:55 am Buzzing: Simmonds Marshall share price rallied 10 percent after ICICI Research said the company has a capital efficient business model where it realises around 3x asset turnover, realises around 12-13 percent EBITDA margins and has a working capital cycle of around 130 days.
DABUR 532538 532978 SIMMOND BHRQY DBRQY GLKQY 505200 500096 500470 MAHSCOOTER UCLQY BHARTIARTL EICHERMOT GLENMARK YESBANK ECQRY JAGRAN 532705 UCLQF 532648 YYBKY 532843 ULTRACEMCO 532454 BAJAJFINSV TTST 532296 INDIANHUME TATASTEEL FORTIS TATLY 500266 504741 507998

0
Indian Hume Pipe bags work order for ₹108 cr from Gujarat govt

2018-04-18 thehindubusinessline
Indian Hume Pipe Company has secured a work order worth ₹108.19 crore from Narmada Water Resources, Water Supply & Kalpsar Department, Gujarat, for a lift irrigation project entailing transmission of 100 cusecs of water from Kherva to Visnagar. Shares of Indian Hume Pipe closed at ₹338.50, down 0.7 per cent, on the NSE.
INDIANHUME 504741

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...